(April 29, 2025, Shanghai, China) On April 29, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”, SSE: 600196, HKEX: 02196),a leading innovation-driven global healthcare company, announced its financial performance for the first quarter of 2025. In the first quarter of 2025, Fosun Pharma achieved operating revenue of RMB9,420 million, net profit attributable to shareholders of RMB765 million, and operating cash flow of RMB1,056 million. Meanwhile, the Group continued to divest and integrate non-strategic and non-core assets to optimizeits asset structure and accelerate cash recovery.

Patients worldwide continue to benefit from innovative achievements

Since 2025, Fosun Pharma further focused on innovative drugs and high-value medical devices, pushing forward its innovation transformation and the development and commercialization of innovative products. In terms of innovative R&D, Fosun Pharma continued to focus on pipelines with advantages, optimized management and resource allocation of R&D projects and prioritized to the promotion of key projects to realize efficient research commercialization and continuous launch of innovative products. In the first quarter of 2025, 2 innovative products independently developed and licensed-in by Fosun Pharma were approved for launch in China and the EU, respectively. Additionally, several innovative pipelines targeting core therapeutic areas like lung cancer and breast cancer had entered the critical clinical/pre-launch approval stage.

In oncology, Fosun Pharma continued to reinforce its leadership in lung cancer, breast cancer, hematologic malignancies, and other tumor domains.The marketing authorization application (MAA) for its self-developed innovative anti-PD-1 monoclonal antibody, Han Si Zhuang (Serplulimab Injection) in combination with carboplatin and etoposide, has been approved for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) by the European Commission (“EC”). The approval indicates that a centralized marketing authorization has been granted in all EU Member States as well as in Iceland, Liechtenstein, and Norway (each a European Economic Area (EEA) country) and establishes serplulimab as the first anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC. To date, Han Si Zhuang has been approved for marketing in over 30 countries and regions, including China, the European Union, and several Southeast Asian nations, benefiting more than 100,000 patients.

In March 2025, the marketing authorization application of Fosun Pharma’s independently developed new drug, Foritinib Succinate Capsules (project code: SAF-189, Foritinib), was accepted by the National Medical Products Administration (NMPA). Foritinib is primarily indicated for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+), etc. The indication under this application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

In March 2025, the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, Fosun Pharma's self-developed innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer (GC). The first Japanese patient has been dosed in the phase 3 international multi-centre clinical trial (HLX22-GC-301) of HLX22 in combination with trastuzumab and chemotherapy for the first-line treatment of HER2-positive advanced gastric/gastroesophageal junction (G/GEJ) cancer.

In breast cancer, a drug registration application for innovative small molecule CDK4/6 inhibitor Fovinaciclib citrate capsules (project code: FCN-437c), independently developed by Avanc Pharma, a subsidiary of Fosun Pharma, has been accepted by the NMPA in January 2025. The indication under the application is hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER2) negative locally advanced or metastatic breast cancer, where it should be used in combination with an aromatase inhibitor as initial endocrine therapy for premenopausal, postmenopausal and perimenopausal women patients with breast cancer.

In non-oncology,Fosun Pharma’s exclusively licensed Wan Ti Le (Tenapanor Hydrochloride Tablets), a First-in-class innovative phosphate absorption inhibitor with a novel mechanism, has received approval from the NMPA with the indication for adult dialysis patients with chronic kidney disease (CKD) in February 2025, offering new hope for patients with hyperphosphatemia on hemodialysis in China.

In March 2025, Fobeni Healthcom Pharmaceutical Jiangsu Company, a joint venture established by Fosun Pharma and Marubeni Corporation, announced the positive results from a double-blind controlled trial (OP0595-5 Trial) in collaboration with Meiji Seika Pharma for the novelβ-lactamase inhibitor (generic name: Nacubactam) in patients with complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AUP).

Strengthen global cooperation and actively promote self-developed products to enter the global market.

In terms ofglobal layout, Fosun Pharma has continued to enhance global license cooperation and actively implemented its internationalization strategy in the first quarter of 2025.

In February 2025, Henlius entered into a license agreement with Dr. Reddy’s for Henlius’ independently developed investigational daratumumab biosimilar HLX15 (a recombinant anti-CD38 fully human monoclonal antibody injection), granting Dr. Reddy’s exclusive rights to commercialize both subcutaneous and intravenous formulations of HLX15 in the U.S. and 42 European countries and regions, boosting the growth and reach of self-developed products in the European and U.S. markets.

In addition, to promote the integration of technological and industrial innovation, in March 2025, Fosun Pharma entered into a strategic partnership with Salus BioMed. The two parties will engage in comprehensive and in-depth cooperation in areas such as product R&D, platform development, and application promotion, to jointly advance technological progress and clinical applications in precision diagnosis and treatment, effectively enhancing the accessibility of innovative diagnostic and therapeutic solutions and benefiting a wide range of patients.

Accelerating A+H shares buyback to boost market confidence

Confident in its sustainable growth and value, Fosun Pharma has actively engaged in share repurchases in both the A-share and H-share markets to enhance investor confidence and protect shareholder interests. In the A-share market, Fosun Pharma initiated the implementation of its 2025 A-share repurchase program on March 26, 2025. As at the end of the Reporting Period, Fosun Pharma had cumulatively repurchased 1,613,300 A-shares, with a total repurchase amount of approximately RMB39.99 million. In the H-share market, Fosun Pharma launched its 2025 H-share repurchase program on January 23, 2025. As at the end of the Reporting Period, Fosun Pharma had cumulatively repurchased 1,655,500 H-shares, with a total repurchase amount of approximately HKD22.91 million.

Looking ahead, Fosun Pharma remains anchored in its core values of“Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy -Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide.

Looking ahead, Fosun Pharma remains anchored in its core values of “Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.

For more information, please visit our official website:www.fosunpharma.com